Compare IDEXX Laboratories, Inc. (IDXX) vs JD.Com Inc (JD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs JD.Com Inc — how do they compare? IDEXX Laboratories, Inc. trades at $532.96 (market cap $40.99B), while JD.Com Inc trades at $26.65 (market cap $36.51B). The key difference: IDEXX Laboratories, Inc. and JD.Com Inc are close in size by market cap, and JD.Com Inc pays a 3.73% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 47 Days and JD.Com Inc for 86 Days on average.
| IDXX | JD | |
|---|---|---|
Market Cap | $40.99B | $36.51B |
Volume | 445,410 | 8,583,924 |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $34.53 |
52-Week Low | $504.70 | $25.19 |
Typical Hold Time | 47 Days | 86 Days |
Enterprise Value | $41.89B | $19.13B |
Dividend Yield | — | 3.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $529.01, up 0.97% with strong fundamental performance including 25.03% net income margin and consistent earnings beats. The stock shows neutral technical signals with support at $518 and resistance at $528. Recent acquisitions like CoVetAI and diagnostic platform expansions demonstrate strategic growth initiatives. Revenue grew from $3.9B in 2024 to $4.3B in 2025 with profit margins expanding to 24.61%.
Outlook remains positive with 56.5% analyst buy ratings and $665 consensus price target representing 25.7% upside. Key risks include FX headwinds and weaker U.S. vet visits, but strong recurring revenue and diagnostic innovation pipeline support long-term growth framework. The company's premium valuation (P/E 36.56) reflects market confidence in sustained profitability.
JD.com trades at $26.68, down 0.15% on the day, with a bearish technical signal driven by moving averages. The stock shows strong analyst support with a consensus price target of $35.38 and a 69.57% buy rating. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.93 surpassing the $0.86 estimate. Revenue for 2025 reached $1.31 trillion, though net income margin declined to 1.49% from 3.56% in 2024. The company is pursuing growth via acquisitions, such as the pending $2.5 billion Ceconomy deal, pending EU approval.
JD.com presents a value opportunity with low valuation multiples (P/E of 17.78, P/S of 0.2) and a robust balance sheet featuring $234 billion in cash. However, risks include regulatory scrutiny from EU probes, competitive pressures in Chinese e-commerce, and margin compression. The stock's upside is supported by strong free cash flow and institutional accumulation, but investors must weigh geopolitical and execution risks against the discounted valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
